Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. VEGFAngiogenesis · 2026
   Article
2. Alternative Splicing in Human Viral Oncogenesis and Tumor Progression.Cancers · 2026
   Review
3. VEGF and Neurotrophins Interaction in the Retinal Neurovascular Unit Homeostasis: A Target for Ocular Disease Treatment and Management.Pharmaceutical research · 2026
   Review
4. Multimodal AI fuses proteomic and EHR data for rational prioritization of protein biomarkers in diabetic retinopathy.medRxiv : the preprint server for health sciences · 2026
   Article
5. Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects.Frontiers in pharmacology · 2026
   Article
6. Repurposing alternative splicing events as potential targets for the design of diagnostic and therapeutic tools in PCa.Frontiers in oncology · 2025
   Review
7. microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis.Journal of bioenergetics and biomembranes · 2022
   Article
8. Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management.Stem cell research & therapy · 2022
   Review
9. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte.Journal of cellular and molecular medicine · 2021
   Article
10. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody.Journal of experimental & clinical cancer research : CR · 2021
    Article
11. A drug-repositioning screen using splicing-sensitive fluorescent reporters identifies novel modulators of VEGF-A splicing with anti-angiogenic properties.Oncogenesis · 2021
    Article
12. Roles of Splicing Factors in Hormone-Related Cancer Progression.International journal of molecular sciences · 2020
    Review
13. Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis.American journal of physiology. Renal physiology · 2019
    Article
14. Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis.Cells · 2019
    Review
15. Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population.PloS one · 2019
    Article
16. Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression.International journal of molecular sciences · 2018
    Review
17. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.International journal of molecular sciences · 2018
    Review
18. Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications.Bladder cancer (Amsterdam, Netherlands)
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

Indexed as